92 related articles for article (PubMed ID: 2027121)
1. Macromolecular markers in joint disease.
Heinegård D; Saxne T
J Rheumatol Suppl; 1991 Feb; 27():27-9. PubMed ID: 2027121
[TBL] [Abstract][Full Text] [Related]
2. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
[TBL] [Abstract][Full Text] [Related]
3. Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse.
Ratcliffe A; Beauvais PJ; Saed-Nejad F
J Orthop Res; 1994 Jul; 12(4):464-73. PubMed ID: 7520485
[TBL] [Abstract][Full Text] [Related]
4. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
Lark MW; Bayne EK; Flanagan J; Harper CF; Hoerrner LA; Hutchinson NI; Singer II; Donatelli SA; Weidner JR; Williams HR; Mumford RA; Lohmander LS
J Clin Invest; 1997 Jul; 100(1):93-106. PubMed ID: 9202061
[TBL] [Abstract][Full Text] [Related]
5. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis.
Lohmander LS; Ionescu M; Jugessur H; Poole AR
Arthritis Rheum; 1999 Mar; 42(3):534-44. PubMed ID: 10088777
[TBL] [Abstract][Full Text] [Related]
6. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
7. Induction of increased levels of proteoglycan fragments in synovial fluid (SF) and increased levels of stromelysin in cartilage, synovium and SF by intraarticular injection of canine monocyte conditioned medium into dogs.
Lark MW; MacNaul KA; Donatelli S; McDonnell J; Hoerrner LA; Stevens KA; Saphos CA; Bayne EK; Hutchinson NI; Moore VL
J Rheumatol; 1994 Sep; 21(9):1716-24. PubMed ID: 7799356
[TBL] [Abstract][Full Text] [Related]
8. Enhanced concentration of COMP (cartilage oligomeric matrix protein) in osteochondral fractures from racing Thoroughbreds.
Skiöldebrand E; Heinegård D; Eloranta ML; Nilsson G; Dudhia J; Sandgren B; Ekman S
J Orthop Res; 2005 Jan; 23(1):156-63. PubMed ID: 15607888
[TBL] [Abstract][Full Text] [Related]
9. [Serum keratan sulfate studies and their significance in the evaluation of cartilage degradation in degenerative and inflammatory joint diseases].
Sárközi AM; Hámori G; Fülöp C; Búzás E; Brózik M; Merétey K; Glant TT
Orv Hetil; 1993 Feb; 134(9):461-7. PubMed ID: 8446416
[TBL] [Abstract][Full Text] [Related]
10. Characterization of monoclonal antibodies recognizing different fragments of cartilage oligomeric matrix protein in human body fluids.
Vilim V; Lenz ME; Vytasek R; Masuda K; Pavelka K; Kuettner KE; Thonar EJ
Arch Biochem Biophys; 1997 May; 341(1):8-16. PubMed ID: 9143347
[TBL] [Abstract][Full Text] [Related]
11. Increased degradation and altered tissue distribution of cartilage oligomeric matrix protein in human rheumatoid and osteoarthritic cartilage.
Di Cesare PE; Carlson CS; Stolerman ES; Hauser N; Tulli H; Paulsson M
J Orthop Res; 1996 Nov; 14(6):946-55. PubMed ID: 8982138
[TBL] [Abstract][Full Text] [Related]
12. Use of synovial fluid markers of cartilage synthesis and turnover to study effects of repeated intra-articular administration of methylprednisolone acetate on articular cartilage in vivo.
Robion FC; Doizé B; Bouré L; Marcoux M; Ionescu M; Reiner A; Poole AR; Laverty S
J Orthop Res; 2001 Mar; 19(2):250-8. PubMed ID: 11347698
[TBL] [Abstract][Full Text] [Related]
13. Cartilage proteoglycan aggrecan as a predictor of joint damage in juvenile rheumatoid arthritis.
el-Sayed ZA; Saleh MT; Al-Wakkad AS; Sherief LS; Nasr el-Din AM
East Mediterr Health J; 2001 Nov; 7(6):992-1003. PubMed ID: 15332741
[TBL] [Abstract][Full Text] [Related]
14. Immunological aspects of markers of joint disease.
Caterson B
J Rheumatol Suppl; 1991 Feb; 27():19-23. PubMed ID: 1709214
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of hyaluronan and proteoglycan in joint disease. Lack of association.
Hedin PJ; Weitoft T; Hedin H; Engström-Laurent A; Saxne T
J Rheumatol; 1991 Oct; 18(10):1601-5. PubMed ID: 1765988
[TBL] [Abstract][Full Text] [Related]
16. The release of aggrecan fragments into synovial fluid after joint injury and in osteoarthritis.
Lohmander LS
J Rheumatol Suppl; 1995 Feb; 43():75-7. PubMed ID: 7752145
[TBL] [Abstract][Full Text] [Related]
17. Differential adherence of osteoarthritis and rheumatoid arthritis synovial fibroblasts to cartilage and bone matrix proteins and its implication for osteoarthritis pathogenesis.
Schedel J; Wenglén C; Distler O; Müller-Ladner U; Schölmerich J; Heinegård D; Krenn V
Scand J Immunol; 2004 Nov; 60(5):514-23. PubMed ID: 15541045
[TBL] [Abstract][Full Text] [Related]
18. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid.
Céleste C; Ionescu M; Robin Poole A; Laverty S
J Orthop Res; 2005 May; 23(3):602-10. PubMed ID: 15885481
[TBL] [Abstract][Full Text] [Related]
19. [Biological markers of osteoarthritis].
Thonar EJ; Manicourt DH
Rev Rhum Ed Fr; 1994 Nov; 61(9 Pt 2):99S-102S. PubMed ID: 7858614
[TBL] [Abstract][Full Text] [Related]
20. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis.
Lohmander LS; Yoshihara Y; Roos H; Kobayashi T; Yamada H; Shinmei M
J Rheumatol; 1996 Oct; 23(10):1765-9. PubMed ID: 8895155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
